Skip to main content
SpringerLink
Log in

Prognostic Biomarkers in Lung Cancer

  • Chapter
  • First Online:
Precision Molecular Pathology of Lung Cancer

Part of the book series: Molecular Pathology Library ((MPLB))

  • 1463 Accesses

Abstract

Predictive biomarkers are valuable in predicting drug response, and their significance increased with the development of targeted therapies in the past decade. In contrast, prognostic biomarkers may allow patients’ risk stratification in relation to specific outcome, usually in the absence of any treatment. The prognostic value of many biomarkers is controversial and mostly reflects differences in study methodologies, patient population, and interpretations. Prognostic biomarkers in lung cancer highly depend on tumor histology. For example, many predictive biomarkers in adenocarcinomas also have prognostic significance. Despite recent biomarker discoveries in squamous cell carcinomas, no well-defined prognostic biomarkers have been established. This chapter will briefly review some of the most important prognostic biomarkers in non-small cell lung carcinoma, primarily adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European thoracic oncology platform lungscape project. J Clin Oncol. 2014;32(25):2780–7.

    Article  PubMed  Google Scholar 

  2. Kim MH, Shim HS, Kang DR, Jung JY, Lee CY, Kim DJ, et al. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Lung Cancer. 2014;83(3):389–95.

    Article  PubMed  Google Scholar 

  3. Mak KS, Gainor JF, Niemierko A, Oh KS, Willers H, Choi NC, et al. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro-Oncology. 2015;17(2):296–302.

    Article  CAS  PubMed  Google Scholar 

  4. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29(26):3574–9.

    Article  CAS  PubMed  Google Scholar 

  5. Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19(16):4532–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29(15):2046–51.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kinno T, Tsuta K, Shiraishi K, Mizukami T, Suzuki M, Yoshida A, et al. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. Ann Oncol. 2014;25(1):138–42.

    Article  CAS  PubMed  Google Scholar 

  8. Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the lung cancer mutation consortium. Cancer. 2015;121(3):448–56.

    Article  CAS  PubMed  Google Scholar 

  9. D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012;7(12):1815–22.

    Article  PubMed  Google Scholar 

  10. Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 2009;4(1):22–9.

    Article  PubMed  Google Scholar 

  11. Jeon JH, Kang CH, Kim HS, Seong YW, Park IK, Kim YT. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection. Eur J Cardiothorac Surg. 2015;47(3):556–62.

    Article  PubMed  Google Scholar 

  12. Lee YJ, Park IK, Park MS, Choi HJ, Cho BC, Chung KY, et al. Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol. 2009;135(12):1647–54.

    Article  CAS  PubMed  Google Scholar 

  13. Liu WS, Zhao LJ, Pang QS, Yuan ZY, Li B, Wang P. Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Med Oncol. 2014;31(1):771.

    Article  PubMed  Google Scholar 

  14. Lim KH, Huang MJ, Liu HC, Kuo HT, Tzen CY, Hsieh RK. Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer. Med Oncol. 2007;24(4):388–93.

    Article  PubMed  Google Scholar 

  15. Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 2008;3(2):111–6.

    Article  PubMed  Google Scholar 

  16. Zhang Z, Wang T, Zhang J, Cai X, Pan C, Long Y, et al. Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis. PLoS One. 2014;9(8):e106053.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141–51.

    Article  CAS  PubMed  Google Scholar 

  18. Zhang Y, Sheng J, Kang S, Fang W, Yan Y, Hu Z, et al. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. PLoS One. 2014;9(9):e107161.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(13):3908–14.

    Article  CAS  PubMed  Google Scholar 

  20. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 2011;17(5):1160–8.

    Article  CAS  PubMed  Google Scholar 

  21. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30(4):433–40.

    Article  CAS  PubMed  Google Scholar 

  22. Ding D, Yu Y, Li Z, Niu X, Lu S. The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis. Onco Targets Ther. 2014;7:387–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17(6):1616–22.

    Article  CAS  PubMed  Google Scholar 

  24. Li W, Ren S, Li J, Li A, Fan L, Li X, et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer. 2014;84(3):295–300.

    Article  PubMed  Google Scholar 

  25. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990;323(9):561–5.

    Article  CAS  PubMed  Google Scholar 

  26. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005;92(1):131–9.

    Article  CAS  PubMed  Google Scholar 

  27. Meng D, Yuan M, Li X, Chen L, Yang J, Zhao X, et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer. 2013;81(1):1–10.

    Article  PubMed  Google Scholar 

  28. Shepherd FA, Domerg C, Hainaut P, Janne PA, Pignon JP, Graziano S, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol. 2013;31(17):2173–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Dimou A, Non L, Chae YK, Tester WJ, Syrigos KN. MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis. PLoS One. 2014;9(9):e107677.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Guo B, Cen H, Tan X, Liu W, Ke Q. Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures. PLoS One. 2014;9(6):e99399.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    Sanja Dacic MD, PhD

Authors
  1. Sanja Dacic MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanja Dacic MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Pathology & Genomic Medici, Houston Methodist Hospital, Houston, Texas, USA

    Philip T. Cagle

  2. Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA

    Timothy Craig Allen

  3. Department of Pathology, Mount Sinai Medical Center, New York, New York, USA

    Mary Beth Beasley

  4. Department of Pathology, Brigham & Women’s Hospital, Boston, Massachusetts, USA

    Lucian R. Chirieac

  5. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

    Sanja Dacic

  6. Department of Pathology, Weill Cornell Medicine, New York, New York, USA

    Alain C. Borczuk

  7. Department of Pathology, Aberdeen University Medical School, Aberdeen, United Kingdom

    Keith M. Kerr

  8. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA

    Lynette M. Sholl

  9. Medical Innovation, Roche Tissue Diagnostics, Ventana Medical Systems, Tucson, Arizona, USA

    Bryce Portier

  10. Cancer Center, Houston Methodist Hospital, Houston, Texas, USA

    Eric H. Bernicker

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Dacic, S. (2018). Prognostic Biomarkers in Lung Cancer. In: Cagle, P., et al. Precision Molecular Pathology of Lung Cancer. Molecular Pathology Library. Springer, Cham. https://doi.org/10.1007/978-3-319-62941-4_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-62941-4_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-62940-7

  • Online ISBN: 978-3-319-62941-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation